ABC3 Consensus Commented from the Perspective of the German Guidelines^[*]

Abstract

The Third International Consensus Conference for Advanced Breast Cancer ABC3 on the diagnosis and treatment of advanced breast cancer was held in Lisbon from 5 to 7 November 2015. This year the focus was the treatment of metastatic breast cancer (stage IV) – including the patient perspectives. Important topics were questions relating to quality of life, the care for long-term survivors as well as the management of disease-related symptoms and treatment-based side effects. The use of standardised tools to assess individual treatment success and the benefits of new substances were important points for discussion. The diagnosis and treatment of inoperable locally advanced breast cancer were discussed two years ago during the ABC2 consensus [1]. A working group of German breast cancer experts commented on the results of the ABC panellists, paying particular attention to the German guidelines (AGO, S3, DGHO) on the diagnosis and treatment of breast cancer [2], [3], [4], [5] in Germany.

Zusammenfassung

Vom 05. bis 07. November 2015 fand in Lissabon die 3. internationale Konsensuskonferenz ABC3 (Advanced Breast Cancer Third Consensus) zu Diagnostik und Behandlung des fortgeschrittenen Mammakarzinoms statt. Der inhaltliche Schwerpunkt lag dieses Jahr auf der Behandlung des metastasierten Mammakarzinoms (Stadium IV) – u. a. unter besonderer Berücksichtigung der Perspektive der Patientinnen. Im Rahmen der Konsensusdiskussion wurde daher auch über Fragestellungen zur Lebensqualität, der Betreuung Langzeitüberlebender sowie des Umgangs mit erkrankungsbedingten Symptomen und therapiebedingten Nebenwirkungen abgestimmt. Neben den klassischen medizinischen Fragestellungen waren der Einsatz standardisierter Instrumente zur Bewertung des individuellen Therapieerfolgs sowie die Nutzenbewertung neuer Substanzen wichtige Diskussionspunkte. Diagnostik und Therapie des inoperablen lokal fortgeschrittenen Mammakarzinoms waren vor 2 Jahren anlässlich des ABC2-Konsensus diskutiert worden [1]. Eine Arbeitsgruppe deutscher Brustkrebsexperten hat die Abstimmungsergebnisse der ABC-Panelisten unter besonderer Berücksichtigung der deutschen Leitlinien (AGO, S3, DGHO) zu Diagnostik und Therapie des Mammakarzinoms [2], [3], [4], [5] für den Therapiealltag in Deutschland kommentiert.

Key words

ABC3 Consensus - Metastatic breast cancer - System therapy - Guidelines

Schlüsselwörter

ABC3-Konsensus - metastasiertes Mammakarzinom - Systemtherapie - Leitlinien

^* The present manuscript (modified version) is a cross-section of opinions from the point of view of German breast cancer experts. The first publication was in “Breast Care” 01/2016 (Thomssen C, Augustin D, Ettl J et al., ABC3-Consensus: assessment by a German group of experts. DOI: 10.1159/000443515). The official ABC3 consensus will be published under the authorship of the ABC3 panelists.

• References

• 1 Cardoso F, Costa A, Norton L et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014; 23: 489-502
• 2 Online: http://www.ago-online.de last access: 15.11.2015
• 3 Liedtke C, Thill M, Hanf V et al. AGO recommendations for diagnosis and treatment of patients with advanced and metastatic breast cancer: update 2015. Breast Care (Basel) 2015; 10: 199-205
• 4 Online: http://www.awmf.org last access: 15.11.2015
• 5 Online: http://www.dgho.de/Onkopedia last access: 24.11.2015
• 6 Cherny NI, Sullivan R, Dafni U et al. A standardized, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
• 7 Schnipper LE, Davidson NE, Wollins DS et al. American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015; 33: 2563-2577
• 8 Online: http://www.junge-erwachsene-mit-krebs.de last access: 15.11.2015
• 9 Swain S, Baselga J, Kim SB et al. Pertuzumab, trastuzumab and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734
• 10 Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791
• 11 Wildiers H, Kim SB, Gonzalez-Martin A et al. T-DM1 for HER2-positive MBC: primary results from TH3RESA, a phase 3 study of T-DM1 vs. treatment of physicianʼs choice. Proc ECC-ESMO 2013; LBA 15.
• 12 Blackwell KL, Burstein HJ, Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 2012; 30: 2585-2592
• 13 Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-444
• 14 Bergh J, Jönsson PE, Lidbrink EK et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012; 30: 1919-1925
• 15 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529
• 16 Finn RS, Crown JP, Lang I et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase-4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). AACR Annual Meeting 2014, San Diego/ZSA, 06. April 2014, CT101.
• 17 ClinicalTrials.gov: NCT01740427. A study of palbociclip + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2− advanced breast cancer.. Online: https://clinicaltrials.gov last access: 15.11.2015
• 18 Turner N, Ro J, Andre F et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; DOI: 10.1056/NEJMoa1505270. http://www.nejm.org/doi/full/10.1056/MEJMoa1505270; last access: 30.11.2015
• 19 Klijn JG, Blamey RW, Boccardo F et al. Combined Hormone Agents Trialistsʼ Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19: 343-353
• 20 Curigliano G. Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients with advanced triple-negative breast cancer. JCO Proc ASCO 2015; #1068.